Amerika'daki Çalışmaları

• Granulocyte-colony stimulating factor (G-CSF) alone for peripheral blood stem cell (PBSC) mobilization in patients with hematologic malignancies.

• Chemotherapy based regimens for cytoreduction and PBSC mobilization in patients with lymphoma, breast and ovarian cancer.

• Cyclophosphamide, paclitaxel and rhG-CSF for cytoreduction and PBSC mobilization in patients with breast and ovarian cancer.

• Busulfan and cyclophosphamide as a conditioning regimen in patients with breast cancer.

• Phase-II study of High-dose chemotherapy with busulfan, melphalan and thiotepa followed by autologous stem cell rescue in patients with advanced stage ovarian cancer.

• Phase I-II trial of allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyper-fractionated total body irradiation in patients with advanced lymphoid malignancies.

• Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation for advanced acute and chronic myelogenous leukemia.

• Phase-I dose escalation of busulfan based on targeted plasma levels: Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for advanced acute and chronic myelogenous leukemia.

• High-dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma.

• Autologous marrow and/or PBSC transplantation in patients with acute myelogenous leukemia: Engraftment characteristics and the incidence of relapse with PBSCs.

• Allogeneic peripheral blood stem cell mobilization and transplantation in patients with advanced hematological malignancies.